Pharmacokinetics of Esomeprazole in Critically Ill Patients

Yanyan Xu1†, Xin Tian2†, Wei Wang2, Weiqiang Tian1, Tao Zhang2, Jian Sun2, Qingyun Zhou3 and Chuxiao Shao3*

1 Department of Pharmacy, Lishui Municipal Central Hospital, Lishui, China, 2 Department of Intensive Care Medicine, Lishui Municipal Central Hospital, Lishui, China, 3 Department of General Surgery, Lishui Municipal Central Hospital, Lishui, China

Background: Esomeprazole, a potent proton pump inhibitor (PPI), is widely used for the prevention of stress ulcers in intensive care unit (ICU) patients.

Objective: This study investigates the pharmacokinetics (PK) of esomeprazole in critically ill patients.

Methods: The study included eligible adult ICU patients who received endotracheal intubation assisted mechanical ventilation for more than 48 h and had at least an extra risk factor for stress ulcers. All enrolled patients received once-daily intravenous (IV) esomeprazole 40 mg. After the first dose of esomeprazole was administrated, serial blood samples were collected at 3, 5, 15, 30 min and 1, 2, 4, 6, 8, and 10 h. The total sample concentrations of esomeprazole were measured by UPLC-MS/MS. Esomeprazole PK parameters were analyzed using noncompartmental analysis.

Results: A total of 30 patients were evaluable. Mean age and body mass index (BMI) were 61.97 years and 23.14. PK sampling on the first dose resulted in the following median (IQR) parameters: AUC0−∞ 8.06 (6.65–9.47) mg·h/L; MRT0−∞ 4.70 (3.89–5.51) h; t1/2 3.29 (2.7–3.87) h; V24.89 (22.09–27.69) L; CL 6.13 (5.01–7.26) L/h; and Cmax 2.56 (2.30–2.82) mg/L.

Conclusions: According to the label of esomeprazole, our study showed different esomeprazole PK parameters in ICU patients compared with healthy volunteers. Esomeprazole has unique pharmacokinetic parameters in critically ill patients.

Keywords: esomeprazole, PK parameters, proton pump inhibitors, CYP2C19, ICU patients

INTRODUCTION

Stress-induced ulcers are extremely common in ICU patients. Because these patients usually have risk factors for stress ulcers, such as coagulopathy, mechanical ventilation for at least 48 h, a Glasgow Coma score of ≤10, or multiple organ dysfunction syndrome (MODS) (1, 2). Approximately 75–100% of ICU patients experience mucosal injury within 24 h of ICU admission. Among them, 5–25% of ICU patients may have obvious bleeding if they do not receive drugs to prevent stress ulcers (3). Multiple studies have reported that stress-related ulcer bleeding may increase the mortality risk of ICU patients (4, 5). Therefore, stress ulcer prophylaxis (SUP) is recommended by many guidelines and expert consensuses, such as the Surviving Sepsis, Stress Ulcer Prophylaxis Campaign, and the Expert Suggestions of Prevention and Treatment of Stress Ulcer (2, 6).
PPIs and histamine 2 receptor antagonists (H2RA) are the two kinds of acid-suppressive agents most commonly used in SUP. However, Meta-analyses show that the PPIs used for SUP can significantly reduce the rate of ulcer bleeding compared with H2RA (7). Esomeprazole is the first (S)-isomer of the PPIs family approved for listing in the United States and major European countries in 2001 with oral and intravenous formulations (8). Esomeprazole is extensively metabolized in the liver by the cytochrome P450 (CYP) enzyme system. The major part of esomeprazole’s metabolism is dependent upon the CYP2C19 isoenzyme, which forms the hydroxyl and desmethyl metabolites. The remaining amount is dependent on CYP3A4 which forms the sulphone metabolite. In CYP2C19 extensive metabolizers, esomeprazole is inactivated at a faster rate. In contrast, CYP2C19 poor metabolizers have approximately twice the level of exposure to esomeprazole. Although genetic variation in CYP2C19 influences the plasma concentration of esomeprazole, the Dutch Pharmacogenetics Working Group of the Royal Dutch Association for the Advancement of Pharmacy (KNMP) recommends that esomeprazole dosage is not changed when CYP2C19 is normal, intermediate, or poorly metabolized (9). Patients with severely impaired hepatic function had a lower rate of metabolism. The AUC was 76% higher than in patients with Gastro-Oesophageal Reflux Disease (GORD) (10).

Numerous clinical trials have demonstrated that esomeprazole has a more pronounced acid-suppressive effect and fewer adverse events than other PPIs (11–13). According to several comparative studies of the acid suppressant efficacy of PPIs, the pharmacokinetic parameters of PPIs are positively correlated with their acid-suppressive effect. Among all PPIs products on the market, esomeprazole has superior pharmacokinetic characteristics and had been proven to be the best acid control effect in the clinical application (10). One study shows that the AUC of esomeprazole was almost 2-fold higher than that of omeprazole at the same dosage (14). The result showed that esomeprazole has a better acid-suppressive effect with a longer duration of intragastric pH > 4 (14). Previous studies on the pharmacokinetics of esomeprazole were carried out in healthy, elderly, patients with symptomatic GORD and patients with hepatic impairment. However, fewer PK parameters of esomeprazole in ICU patients were reported. ICU patients were critically ill with multiple-organ dysfunction, hypoalbuminaemia, and extracorporeal clearance techniques. Drug pharmacokinetic characteristics are often different from healthy subjects. Therefore, the objective of this trial was to describe the PK of a single dose of i.v. esomeprazole in critically ill patients.

MATERIALS AND METHODS

Study Design

This open-label, single-treatment exploratory trial of IV esomeprazole was conducted in an Intensive Care Unit with critically ill patients with at least one additional risk factor for stress ulcer (Clinical Trial Registry, ChiCTR1800018516). The study protocol was approved by the Ethics Committee of Lishui Hospital of Zhejiang University (Ethical Review of Clinical Research-2016-43) and adhered to the tenets of the Declaration of Helsinki. Informed consent was obtained from the patients or the patients’ legally authorized representative.

Patients aged 18–89 years who were admitted to ICU and receiving esomeprazole for the prophylaxis of stress-related mucosal disease were eligible to participate. Exclusion criteria included lactation or pregnancy, clinical diagnosis of treat peptic ulcer bleeding, peptic/stomach ulcer, gastroesophageal reflux disease, and Zollinger-Ellison syndrome, or the dosage of esomeprazole >40 mg in 1 day for other purposes. Patients also were excluded if they had a history of treated peptic ulcer bleeding, peptic/stomach ulcer, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. All eligible patients received IV esomeprazole 40 mg once a day by the site nurse from the central vein. Each dose was injected slowly with 5 min. After IV esomeprazole 40 mg was administered, blood samples of 1.0 mL were drawn from the basilic vein: at 3, 5, 15, 30 min and 1, 2, 4, 6, 8, and 10 h. All blood samples were stored at room temperature for 30 min after collection and then centrifuged at 1500 g for 10 min at room temperature. Plasma was aspirated and transferred into a labeled 1.5 mL Eppendorf tube and stored at −80°C immediately after aspiration until drug assay. Patients were eligible if the PK curve was completed.

Baseline Parameters

Upon inclusion, the baseline parameters of each patient were registered: gender, age, weight, BMI, alanine transaminase (ALT), aspartate transaminase (AST), blood urine nitrogen (BUN), creatinine clearance rate (CCR), APACHE II score (within 24 h of ICU admission), and Child-Pugh class.

Sample Measurement

Blood samples were collected according to the scheduled time and the concentration of esomeprazole in plasma and were determined by UPLC-MS/MS according to a previous method [15]. The chromatographic column was the ACQUITY UPLC BEH C18 column (2.1× 50 mm, 1.7 um). Esomeprazole was separated by gradient elution, which consisted of mobile phase A acetonitrile and A 0.1% formic acid and 5 mM ammonium formate in water. Gradient condition was detailed as follows: total run time was 3 min. Initially, mobile phase A was sustained as 20% from 0 to 0.7 min. Ten, A was reached to 80% for the 0.9 min. Ten 80% of mobile phase A was maintained for 0.5 min. Next, the mobile phase A was drawn back to 20% for 0.7 min and equilibrated as 20% for the 2 min. The flow rate was 0.40 ml/min, and the column was 40°C. Detection was conducted with a triple quadrupole tandem mass spectrometer equipped with positive electrospray ionization (ESI) by multiple reactions monitoring (MRM) of the transitions. The ion transitions were m/z 346.2 >198.0 for esomeprazole and m/z 285.1 > 193.1 for diazepam (internal standard).

CYP2C19 Genetic Analysis

Genetic polymorphism of cytochrome CYP2C19 was detected by DNA microarray, which was reported in our previous study (15). In brief, 4 mL of whole blood samples were collected from each patient; the DNA was extracted from the blood using a Blood
Genomic DNA Extraction Kit, then the concentration and purity of extracted DNA was determined by spectrophotometry. The variants of the CYP2C19 gene were detected by a commercially available kit (BaiO Technology Co, Ltd., Shanghai, China). Six genotypes of CYP2C19 were classified as three metabolic phenotypes. CYP2C19 genotype of *1/*1 is a normal metabolizer (NM). The intermediate metabolizer (IM) includes the CYP2C19 genotype of *1/*2 and *1/*3. The poor metabolizer (PM) includes CYP2C19 *2/*2, *2/*3 or *3/*3.

### Pharmacokinetic Analyzes

PK parameters of esomeprazole were calculated according to the plasma concentration-time profiles, which were analyzed by a noncompartmental model analysis in DAS 3.2.8 (Drug and Statistics 3.2.8, Shanghai China). Pharmacokinetic analyses were performed with evaluable data from patients who were eligible for the study and had a sufficient number of data points. The areas under the concentration of esomeprazole in the plasma vs. the time curve from time zero to infinity (AUC$_{0-\infty}$) were calculated by the linear trapezoidal rule and the standard area extrapolation method. MRT was calculated as AUMC$_{0-\infty}$/AUC$_{0-\infty}$. The plasma clearance (CL) was estimated as Dose/AUC$_{0-\infty}$. Plasma terminal half-life (t$_1/2$) was calculated as ln2/λz, while λz is the terminal slope of the log plasma esomeprazole concentration-time profile. V was calculated as MRT× CL. The maximum esomeprazole concentration (C$_{max}$) was directly determined from the plasma esomeprazole concentration-time curves.

### Statistical Analysis

The values for pharmacokinetic variables were stated as estimates with 95% confidence intervals for the true geometric means. All continuous variables were tested for normality by the Kolmogorov-Smirnov test. The data of skewed distribution were transformed into the log-normal distribution. After normal testing, statistical analysis was conducted by SPSS 20.0 using ANOVA. The changes of six main pharmacokinetic parameters of both liver function classification and CYP 2C19 polymorphism were analyzed by multivariate analysis of variance. $P < 0.05$ was considered to be significantly significant.

### RESULTS

#### Patients

All 30 participants completed the study. Baseline characteristics are summarized in Table 1. The patients were two/thirds of men, aged 18–88 years, and had a mean APACHE II score of 21.10. Other baseline characteristics were: mean body mass index 23.14 kg/m$^2$, mean Child-Pugh score 6.37, mean creatinine clearance rate 91.32 mL/min, and mean albumin 29.90 g/L. 63.33% of participants had three or more additional stress ulcer risk factors.

#### Esomeprazole PK

The geometric means (95% CI) of the PK parameters are presented in Table 2. Figure 1 shows the mean esomeprazole concentration profiles of a single i.v. dose of 40 mg over 10 h after administration.

### Effect of CYP2C19 Metabolic Phenotype

The pharmacokinetic results were analyzed according to the CYP2C19 metabolic phenotype in Table 3. The PK parameters except for C$_{max}$ were slightly different between NM, IM, and PM. NM and IM individuals had higher values of AUC$_0-\infty$, MRT$_0-\infty$, t$_1/2$, and V. However, PM individuals had higher CL values than NM and IM individuals.
TABLE 3 | Comparison of esomeprazole PK parameters with various CYP2C19 metabolic phenotype.

| Variable | Normal metabolizers (NM, n = 12) | Intermediate metabolizers (IM, n = 15) | Poor metabolizers (PM, n = 3) | P-value |
|----------|----------------------------------|---------------------------------------|-----------------------------|---------|
| AUC_{0-\infty} | 8.29 (6.07–10.50) | 8.34 (5.97–10.71) | 5.76 (1.09–10.42) | 0.56 |
| MRT_{0-\infty} | 5.08 (3.70–6.46) | 4.58 (3.32–5.83) | 3.84 (-1.27–8.96) | 0.66 |
| t_{1/2} | 3.67 (2.61–4.73) | 3.18 (2.31–4.05) | 2.33 (0.46–4.21) | 0.40 |
| V | 26.30 (19.88–32.71) | 24.00 (20.87–27.13) | 3.84 (-1.27–8.96) | 0.72 |
| CL | 5.57 (4.07–7.06) | 6.29 (4.33–8.25) | 7.59 (0.23–14.95) | 0.58 |
| C_{max} | 2.56 (2.07–3.06) | 2.53 (2.24–2.83) | 2.67 (-0.45–5.78) | 0.96 |

DISCUSSION

According to the instructions of esomeprazole, the results of this study indicated that the esomeprazole PK parameters in critically ill patients were different from those in healthy volunteers. We observed highly variable PK parameters, in particular for the observed volume of drug distribution (V) and clearance (CL). Compared with the values reported for Chinese healthy volunteers, the value of V 24.89 (22.09–27.69) L in critically ill patients was 1.88 times higher and the value of CL 6.13 (5.01–7.26) L/h was 35.85% lower (16).

Compared with healthy volunteers, many factors such as increased total body water and interstitial or ‘third space’ fluid volumes, decreased albumin concentration, plasma pH changed, peripheral tissue penetration changed during septic shock, and increased permeability of the blood-brain barrier (BBB) that may influence drug distribution among critically ill patients (17). Therefore, V for hydrophilic drugs such as β-lactam antibiotics was increased in critically ill patients (18). The value of V (24.89 L) was nearly double that of healthy volunteers (13.32 L) (16), suggesting that esomeprazole was distributed more extensively in critically ill patients. Esomeprazole is a high protein binding drug and its protein binding rate is 97%. Therefore, unbound esomeprazole plasma concentration is increased in hypoproteinemia patients. According to the baseline characteristics of all participants, the mean albumin concentration was 29.90 g/L lower than normal values. Hypoproteinemia is one reason for high V. There were 10 participants of sepsis. High peripheral tissue penetration during septic shock also is one reason for high V. In addition, critically ill patients often have increased total body water and interstitial or “third space” fluid volumes were the most common factors that led to elevated V.
The CL in this study was 6.13 L/h, which was far lower than Chinese healthy volunteers 17.1 L/h (16). This means that esomeprazole was slowly cleared with longer residence time in vivo. Esomeprazole was the drug mainly metabolized by the liver CYP2C19 isoenzyme and nearly 80% was excreted from urine in the form of metabolites according to its drug instructions. CL could be affected by liver dysfunction, renal dysfunction, continuous renal replacement therapy (CRRT), and extracorporeal membrane oxygenation (ECMO) (17). There were 12 participants of Child-Pugh grade B, individuals with mild to moderate hepatic dysfunction could affect the reduced CL. CCR was 10.67–207.82 mL/min with high individual variability. Moderate-to-severe renal impairment also caused the reduced CL. In addition, the elevated V of esomeprazole was widely distributed in critically ill patients, which could lead to low clearance.

As $t_{1/2}$ is proportional to V and inversely proportional to CL, the impact of a change in V during critical illness on the overall pharmacokinetics of esomeprazole likely depends on whether CL is affected. The mean $t_{1/2}$ of esomeprazole in this study (3.29 h) was much higher than that reported in healthy volunteers (mean, 0.85 h) (10). This observation was consistent with the fact that clearance was reduced while the volume of distribution was increased, which would result in an increased elimination half-life (elimination rate constant $k = CL/V$) (15). This indicated that the retention time of esomeprazole in critically ill patients is prolonged.

AUC$_{0-\infty}$ is another important PK parameter in these special patients. The mean AUC$_{0-\infty}$ in this study (8.06 mg·h/L) was nearly more than three times the value described in healthy volunteers after a single intravenous dose of 40 mg (6.84 µmol·h/L) (16), when they were converted into unified units. Similarly, $C_{\text{max}}$ was increased in critically ill patients. $C_{\text{max}}$ of healthy volunteers (5.53 µmol/L) was only 74.6% of the value in critically ill patients (18). This was in line with the elevated V and reduced CL we observed. According to a previous report (10), esomeprazole had a clear AUC-effect relationship. AUC was correlated to the inhibitory effect on stimulated gastric acid secretion. Therefore, we speculated that the increased esomeprazole concentration exposure in blood with high AUC and $C_{\text{max}}$ in critically ill patients could have a more effective acid control effect. The special pathological characteristics of critically ill patients caused AUC and $C_{\text{max}}$ to change. Furthermore, the increased unbound fraction resulting from the low plasma albumin levels means that more free-drug was available for elimination, which is consistent with the increased $C_{\text{max}}$ we observed in this study.

Esomeprazole is extensively metabolized in the liver by the human cytochrome P450 (CYP) enzyme system. According to the label for esomeprazole (Nexium IV), in patients with liver impairment, the dosage of esomeprazole should be adjusted based on Child-Pugh grade when esomeprazole was used to rebleeding of gastric or duodenal ulcers following therapeutic endoscopy. In order to evaluate the effect of the liver impairment on esomeprazole PK, we divided the participants into Child A group or Child B group according to their Child-Pugh score. Compared with the Child A group, AUC$_{0-\infty}$, $C_{\text{max}}$, $t_{1/2}$, and V of esomeprazole in the Child B group were increased by 1.10, 1.27, 1.32, and 1.15-fold, but CL and $C_{\text{max}}$ in Child B group were decreased to 94.80% and 85.29%. These PK parameters showed critically ill patients with severe liver impairment had wider distribution and longer retention of esomeprazole in the body. However, for the PK parameters, there was no significant difference between the two groups. This was because many factors could affect the metabolism of

### TABLE 4 | Comparison of esomeprazole pharmacokinetic parameters with various Child-Pugh grade.

| Variable          | Child A (n = 18) | Child B (n = 12) | P-value |
|-------------------|-----------------|-----------------|---------|
| AUC$_{0-\infty}$  | 7.74 (6.07–9.40) | 8.55 (5.70–11.39) | 0.58    |
| MRT$_{0-\infty}$  | 4.25 (3.41–5.10) | 5.36 (3.69–7.07) | 0.17    |
| $t_{1/2}$         | 2.91 (2.31–3.50) | 3.86 (2.65–5.08) | 0.10    |
| V                 | 23.51 (20.16–26.85) | 32.93 (21.61–32.32) | 0.22    |
| CL                | 6.29 (4.70–7.87) | 5.90 (4.08–7.73) | 0.74    |
| $C_{\text{max}}$  | 2.72 (2.34–3.10) | 2.32 (2.00–2.65) | 0.13    |

### TABLE 5 | Comparison of esomeprazole pharmacokinetic parameters with various Child-Pugh grade and CYP2C19 metabolic phenotype.

| PK          | Child A    | Child B     |     |
|-------------|------------|-------------|-----|
| AUC$_{0-\infty}$ | Normal metabolizers | 8.62 (8.49–9.20) | 7.31 (4.70–7.47) |     |
|             | Intermediate metabolizers | 6.97 (4.71–10.62) | 10.81 (4.89–13.25) |     |
|             | Poor metabolizers | 6.40 (3.64–7.23) | / |     |
| MRT$_{0-\infty}$ | Normal metabolizers | 4.82 (3.75–6.61) | 4.84 (3.27–7.32) |     |
|             | Intermediate metabolizers | 3.46 (2.73–5.55) | 5.95 (2.93–8.67) |     |
|             | Poor metabolizers | 3.41 (2.03–6.08) | / |     |
| $t_{1/2}$   | Normal metabolizers | 3.71 (2.35–4.82) | 3.65 (2.17–5.94) |     |
|             | Intermediate metabolizers | 2.62 (1.63–3.63) | 4.31 (2.20–5.83) |     |
|             | Poor metabolizers | 2.15 (1.68–3.16) | / |     |
| V           | Normal metabolizers | 24.82 (15.20–31.59) | 26.97 (21.61–32.32) |     |
|             | Intermediate metabolizers | 24.57 (16.90–28.85) | 23.50 (22.67–27.79) |     |
|             | Poor metabolizers | 25.21 (19.36–26.62) | / |     |
| CL          | Normal metabolizers | 4.64 (4.35–4.71) | 5.47 (5.35–8.51) |     |
|             | Intermediate metabolizers | 5.76 (3.94–8.72) | 3.70 (3.11–8.40) |     |
|             | Poor metabolizers | 6.25 (5.53–10.99) | / |     |
| $C_{\text{max}}$ | Normal metabolizers | 2.84 (2.50–3.87) | 2.20 (1.63–2.50) |     |
|             | Intermediate metabolizers | 2.45 (2.14–2.90) | 2.71 (2.13–2.85) |     |
|             | Poor metabolizers | 2.08 (1.82–4.10) | / |     |
TABLE 6 | Tests of between Child-Pugh grade and CYP2C19 metabolic phenotype Effects.

| Source | Type III sum of squares | df | Mean square | F-value | Sig. |
|--------|-------------------------|----|-------------|---------|------|
| Corrected model | 28.746 | 4 | 7.187 | 0.464 | 0.761 |
| Intercept | 1325.392 | 1 | 1325.392 | 85.624 | 0.000 |
| Child-Pugh grade | 0.858 | 1 | 0.858 | 0.055 | 0.816 |
| CYP2C19 metabolic phenotype | 16.855 | 2 | 8.427 | 0.544 | 0.587 |
| Child-Pugh grade* CYP2C19 | 9.754 | 1 | 9.754 | 0.630 | 0.435 |
| Dependent variable: MRT<sub>0-∞</sub> | 15.920 | 4 | 3.980 | 0.826 | 0.521 |
| Intercept | 493.836 | 1 | 493.836 | 102.459 | 0.000 |
| Child-Pugh grade | 5.203 | 1 | 5.203 | 1.080 | 0.309 |
| CYP2C19 metabolic phenotype | 1.302 | 2 | 0.651 | 0.135 | 0.874 |
| Child-Pugh grade* CYP2C19 | 5.768 | 1 | 5.768 | 1.197 | 0.284 |
| Dependent variable: t<sub>1/2</sub> | 10.768 | 4 | 2.692 | 1.117 | 0.371 |
| Intercept | 234.154 | 1 | 234.154 | 97.125 | 0.000 |
| Child-Pugh grade | 3.271 | 1 | 3.271 | 1.357 | 0.255 |
| CYP2C19 metabolic phenotype | 2.006 | 2 | 1.003 | 0.416 | 0.664 |
| Child-Pugh grade* CYP2C19 | 2.397 | 1 | 2.397 | 0.994 | 0.328 |
| Dependent variable: V | 110.896 | 4 | 27.724 | 0.454 | 0.768 |
| Intercept | 13605.724 | 1 | 13605.724 | 222.913 | 0.000 |
| Child-Pugh grade | 64.075 | 1 | 64.075 | 1.050 | 0.315 |
| CYP2C19 metabolic phenotype | 16.530 | 2 | 8.265 | 0.135 | 0.874 |
| Child-Pugh grade* CYP2C19 | 10.168 | 1 | 10.168 | 0.167 | 0.687 |
| Dependent variable: CL | 26.159 | 4 | 6.540 | 0.686 | 0.608 |
| Intercept | 842.319 | 1 | 842.319 | 88.402 | 0.000 |
| Child-Pugh grade | 0.167 | 1 | 0.167 | 0.018 | 0.896 |
| CYP2C19 metabolic phenotype | 10.757 | 2 | 5.378 | 0.564 | 0.576 |
| Child-Pugh grade* CYP2C19 | 15.641 | 1 | 15.641 | 1.642 | 0.212 |
| Dependent variable: C<sub>max</sub> | 2.654 | 4 | 0.663 | 1.478 | 0.239 |
| Intercept | 143.061 | 1 | 143.061 | 318.650 | 0.000 |
| Child-Pugh grade | 1.382 | 1 | 1.382 | 3.078 | 0.092 |
| CYP2C19 metabolic phenotype | 0.120 | 2 | 0.060 | 0.134 | 0.875 |
| Child-Pugh grade* CYP2C19 | 1.402 | 1 | 1.402 | 3.122 | 0.089 |

Esomeprazole during critical illness, such as CYP2C19 genotype difference, administration of a CYP2C19 inhibitor or two drugs metabolized by the same CYP2C19 resulting in competitive inhibition, administration of an agent that induces CYP2C19, reduced hepatic or splanchnic blood flow as a result of shock, acute renal failure or increased protein binding to albumin or α<sub>1</sub>-acid glycoprotein, Gram-negative sepsis associated with the production of LPS and increased global or locoregional production of proinflammatory cytokines, surgical interventions and so on (17). In this study, the combined drugs of the enrolled cases were vasoactive drugs (norepinephrine), opioid analgesics (morphine, fentanyl), sedatives (midazolam, dexmedetomidine), antibiotics (imipenem cilastatin, piperacillin tazobactam, cefoperazone sulbactam, vancomycin), albumin and crystalloid fluid. These combined drugs with no clear reports of drug interaction with EPZ.

According to the label for esomeprazole (Nexium IV), CYP2C19 is the major metabolic enzyme, while the CYP2C19 poor metabolizers (PM) genotype is common in Asian populations with a ratio of 15–20%. The difference of the individual CYP2C19 genotype resulted in different PK and PD. At a steady state, the ratio of AUC in Poor Metabolizers to the rest of the population (Extensive metabolizers) is approximately 2 (14). In the current study, six genotypes of CYP2C19 were classified into three metabolic phenotypes, normal metabolizer (NM), intermediate metabolizer (IM), and poor metabolizer (PM). Compared with the PM group, the mean AUC<sub>0-∞</sub> of esomeprazole were 1.44 and 1.45-fold higher than NM and IM groups. However, the ratio of AUC<sub>0-∞</sub> between different CYP2C19 phenotypes was much lower than that reported in healthy volunteers (19). t<sub>1/2</sub> in NM and IM groups were longer than PM group, while CL in NM and IM groups were lower.
than the PM group. The results of $t_{1/2}$ and CL were inconsistent with the previous study (20). We speculated that the main reason was the small sample size with only three patients in the PM group.

There are two limitations of this study. One limitation is the small sample size of the PM group. Given the adequate sample size of the NM, IM, and PM groups, we can obtain the pharmacokinetic characteristics of critical patients with different CYP phenotypes. The other limitation is that the pharmacodynamics of the anti-acid effect and effective maintenance time at target pH after intravenous administration of esomeprazole were not designed. Further PK/ PD model clinical studies of esomeprazole plasma concentration with effects on 24 h intragastric pH levels are necessary to establish the scientific dosage regimen of critically ill patients. We recommend that further studies based on the population PK and PD are essential, for more data are required to promote the rational use of esomeprazole in critically ill patients.

CONCLUSIONS

The PK of a single dose of 40 mg i.v. esomeprazole in critically ill patients was different from the PK data reported by previous studies in healthy volunteers receiving the same i.v. dose of 40 mg.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: Figshare (https://doi.org/10.6084/m9.figshare.13141406.v2 and https://doi.org/10.6084/m9.figshare.17019536).

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of Lishui Municipal Central Hospital. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

CS, YX, and XT participated in the design of this study and they both performed the statistical analysis. WT and QZ tested the blood concentration. YX and WT carried out pharmacokinetic analyzes. WW, TZ, and JS managed patients and collected data. YX drafted the manuscript. All authors read and approved the final manuscript.

FUNDING

This material is based upon work supported by the Beijing Medical and Health Foundation of China under grant no. YWJJKJHYJJ-212, Zhejiang Provincial Natural Science Foundation of China under grant no. LY18H300007, High Level Talented Person Cultivating Program of Lishui Science and Technology Bureau under grant no. 2018RC06, and Zhejiang TCM science and technology program under grant no. 2013BZ148.

REFERENCES

1. Barletta JF, Bruno JJ, Buckley MS, Cook DJ. Stress ulcer prophylaxis. Crit Care Med. (2016) 44:1395–405. doi: 10.1097/CCM.0000000000001872
2. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. (2017) 43:304–77. doi: 10.1007/s00134-017-4683-6
3. Rafinazari N, Abbasi S, Farsaei S, Mansourian M, Adibi P. Adherence to stress-related mucosal damage prophylaxis guideline in patients admitted to the intensive care unit. J Res Pharm Pract. (2016) 5:186–92. doi: 10.4103/2279-042X.185728
4. Buendgens L, Koch A, Tacke F. Prevention of stress-related ulcer bleeding at the intensive care unit: risks and benefits of stress ulcer prophylaxis. World J Crit Care Med. (2016) 5:57–64. doi: 10.5492/wjccm.v5i11.57
5. Lou W, Xia Y, Xiang P, Zhang L, Yu X, Lim S, et al. Prevention of upper gastrointestinal bleeding in critically ill patients: a randomized, double-blind study evaluating esomeprazole and cimetidine. Curr Med Res Opin. (2018) 34:1449–55. doi: 10.1080/03007995.2018.1464132
6. Bai Y, Li YQ, Ren X, Li ZS. Expert group on prevention and treatment of stress ulcer. Expert suggestions on prevention and treatment of stress ulcer 2018. Natl Med J China. (2018) 98:3392–5. doi: 10.3760/cma.j.issn.0376-2491.2018.42.003
7. Barkun AN, Bardou M, Pham CQ, Martel M. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis. Am J Gastroenterol. (2012) 107:507–20. doi: 10.1038/ajg.2011.474
8. Yang L, Yan BX. Pharmacokinetics of esomeprazole. Chin J New Drug. (2004) 13:398–400. doi: 10.3321/j.issn:1003-3734.2004.05.005
9. Dean L. Esomeprazole therapy and CYP2C19 genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel R, Kane MS, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda, MD: National Center for Biotechnology Information (US) (2012).
10. Anderson T, Hassan-Alin M, Hasselgren G, Röhss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. (2001) 40:411–26. doi: 10.2165/00003088-200100070-00004
11. Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Iwaizumi M, et al. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol Ther. (2013) 38:1129–37. doi: 10.1111/apt.12492
12. Morgan D, Pandolfino J, Katz PO, Goldstein JL, Barker PN, Ilueca M. Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther. (2010) 32:200–8. doi: 10.1111/j.1365-2036.2010.04335.x
13. Miner PJ, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. (2003) 98:2616–20. doi: 10.1111/j.1572-0241.2003.08783.x
14. Lind T, Rydberg L, Kyleback A, Jonsson A, Andersson T, Hasselgren G, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. (2000) 14:861–7. doi: 10.1046/j.1365-2036.2000.00813.x
15. Tian H, Xu Y, Wang J, Tian W, Sun J, Zhang T, et al. Effects of plasma albumin on the pharmacokinetics of esomeprazole in ICU patients. Biomed Res Int. (2018) 2018:6374374. doi: 10.1155/2018/6374374
16. Liu D, Yang H, Jiang J, Nagy P, Shen K, Qian J, et al. Pharmacokinetic and pharmacodynamic modeling analysis of intravenous esomeprazole in healthy volunteers. J Clin Pharmacol. (2016) 56:816–826. doi: 10.1002/jc ph.733

17. Roberts, DJ, Hall RI. Drug absorption, distribution, metabolism and excretion considerations in critically ill adults. Expert Opin Drug Metab Toxicol. (2013) 9:1067–1084. doi: 10.1517/17425255.2013.7 99137

18. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. (2009) 37:840– 51. doi: 10.1097/CCM.0b013e3181961b7f

19. Hassan-Alin M, Andersson T, Bredberg E, Röhss K. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol. (2000) 56:665– 70. doi: 10.1007/s002280000206

20. Sugimoto M, Furuta T. Efficacy of esomeprazole in treating acid-related diseases in Japanese populations. Clin Exp Gastroenterol. (2012) 5:49– 59. doi: 10.2147/CEG.S23926

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.